- Home
- EUDA vs PRLD Comparison
EUDA vs PRLD Comparison
Compare EUDA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EUDA | PRLD |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EUDA | PRLD |
|---|---|---|
| Price | $2.27 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 36.8K | ★ 465.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $5,160,280.00 | ★ $10,500,000.00 |
| Revenue This Year | $137.25 | N/A |
| Revenue Next Year | $361.43 | N/A |
| P/E Ratio | $313.71 | ★ N/A |
| Revenue Growth | 83.73 | ★ 250.00 |
| 52 Week Low | $1.03 | $0.61 |
| 52 Week High | $6.30 | $4.22 |
Technical Indicators
Market Signals| Indicator | EUDA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 53.95 |
| Support Level | $2.81 | $1.30 |
| Resistance Level | $3.21 | $1.56 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 3.42 | 100.00 |
Price Performance
Historical ComparisonAbout EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.